Review: Interferon-α plus ribavirin improves the virologic response in chronic hepatitis C

Reichen, Juerg
July 2002
ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p17
Academic Journal
Provides information on a study that examined whether interferon-α plus ribavirin more effective than interferon-α alone for improving hepatitis C virologic response and liver-related morbidity and mortality in patients with chronic hepatitis C. Data sources; Study selection; Main results; Conclusion.


Related Articles

  • HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Romero-Gómez, Manuel; González-Escribano, María Francisca; Torres, Belén; Barroso, Natalia; Montes-Cano, Marco Antonio; Sánchez-Muñoz, Diego; Núñez-Roldan, Antonio; Aguilar-Reina, José // American Journal of Gastroenterology;Jul2003, Vol. 98 Issue 7, p1621 

    : ObjectiveThe aim of this study was to assess the influence of host genetic factors on response to combination therapy for chronic hepatitis C infection.: MethodsPatients with biopsy-proved chronic hepatitis C infection were treated with interferon alone (n = 143) or combined therapy of...

  • Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Lee, Silvia; Macquillan, Gerry C; Keane, Niamh M; Flexman, James; Jeffrey, Gary P; French, Martyn Ah; Brochier, Jean; Price, Patricia // Immunology & Cell Biology;Aug2002, Vol. 80 Issue 4, p391 

    Summary Type 1 (T1) cytokine responses are required for the clearance of hepatitis C virus by cytotoxic T lymphocytes, but can promote liver damage. Interferon-α (IFNα) can be expected to promote T1 cytokine responses, so treatment outcome may depend on the T1/T2 cytokine environment and...

  • Interferon-α-2b Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C. Scott, L.J.; Perry, C.M. // Drugs;2002, Vol. 62 Issue 3, p507 

    Relatively few patients (≤20%) with chronic hepatitis C achieve a sustained virological response after interferon-α monotherapy. Hence, alternative treatment strategies such as the addition of the broad spectrum antiviral agent ribavirin to interferon-α-2b have been investigated....

  • Interferon affacon-1.  // Formulary;May2005, Vol. 40 Issue 5, p168 

    Reports on successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin.

  • Modifications of the Immune Responsiveness in Patients with Hepatitis C Virus Infection following Treatment with IFN-a / Ribavirin. Caradonna, L.; Mastronardi, M.L.; Amati, L.; Magrone, T.; Cuppone, R.; Cozzolongo, R.; Manghisi, O.G.; Caccavo, D.; Amoroso, A.; Jirillo, E. // Current Pharmaceutical Design;May2002, Vol. 8 Issue 11, p981 

    The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-?)] have been demonstrated to mediate the antiviral immune response. Serum levels of...

  • Therapy of Chronic Hepatitis C: A Critical Review. Saracco, G.; Olivero, A.; Ciancio, A.; Carenzi, S.; Rizzetto, M. // Current Drug Targets - Infectious Disorders;Mar2003, Vol. 3 Issue 1, p25 

    Combination therapy (Interferon plus ribavirin) is the current therapeutic gold standard for naive Hepatitis C Virus (HCV)-positive patients and with the recent advent of pegylated (PEG) IFN the rate of the sustained virological response (HCV-RNA clearance 6 months after the end of treatment) is...

  • Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial. Adinolfi, L.E.; Utili, R.; Tonziello, A.; Ruggiero, G. // Gut;May2003, Vol. 52 Issue 5, p701 

    Background: Fifty per cent of chronic hepatitis C patients are non-responders to interferon. At present, there are no recommended therapeutic options for non- responders. Aims: The safety and long term effect of alpha interferon induction plus ribavirin with or without amantadine in the...

  • Interferon-α Alone versus Interferon-α plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-α Treatment. Tripi, S.; Di Gaetano, G.; Soresi, M.; Cartabellotta, F.; Vassallo, R.; Carroccio, A.; Anastasi, G.; Montalto, G. // BioDrugs;2000, Vol. 13 Issue 4, p299 

    Objective: To study the effects of monotherapy with leucocyte interferon-α (IFNα) versus IFNα + ribavirin in patients with chronic hepatitis C who were nonresponders to previous courses of recombinant or lymphoblastoid IFNα. Design and setting: This was a nonblind randomised study of...

  • Peginterferon-α-2b/ribavirin.  // Reactions Weekly;10/20/2007, Issue 1174, p23 

    The article describes the case of a 42-year-old woman who developed diabetic ketoacidosis while receiving peginterferon-α-2b and ribavirin. The woman was receiving the medication because she has chronic hepatitis C. The symptoms presented by the patients 2 months after receiving the regimen...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics